Designed for you.

VAXXITEK® HVT+IBD+ND represents a breakthrough in hatchery vaccination. A 3-in-1 vaccine, it provides a strong immune foundation and optimized protection against Marek’s disease (MD), infectious bursal disease (IBD) and Newcastle disease (ND).1

  • All the benefits of VAXXITEK® HVT+IBD, now designed with ND protection
  • Simplified vaccination protocol that protects against 3 of the most infectious and commercially disruptive flock diseases
  • Herpesvirus of turkeys (HVT)-based vector vaccine; worldwide renowned technology
  • Safe and easy to use

Key advantages

  • One single vaccination to protect against IBD, MD, and ND1
  • Early onset and long duration of immunity, for protection throughout susceptible periods1
  • Demonstrated safety by monitoring of body weight gain, for improved production performance1
  • Genotype VII ND insert, for universal protection
  • Efficient protection against a variety of IBD virus (IBDV) strains2-4
  • Rapid and long-lasting protection against velogenic ND virus5-7
  • Onset of immunity against MD shown from 5 days of age8,9
  • 3-in-1 vaccine: MD, IBD, and ND protection
  • Same technology platform as VAXXITEK® HVT+IBD that ensures proper gene expression
  • Strong immune foundation enables productivity, reduces antibiotic use, and supports return on investment
  • Reduced labor, time, and cost enable increased profitability
  • Improved animal welfare through fewer vaccine applications
  • Only one hatchery administration at 1 day of age or in ovo

Package in 5 x 4000 dose ampules in frozen presentation

KDS Code: RMGNF9865 

  • Do not mix with other products, except as specified on the label
  • In case of human exposure, contact a physician
  • Administer only as recommended
  • Use entire contents when first opened
  • Do not vaccinate within 21 days before slaughter
  • Contains penicillin and streptomycin sulfate, which are added as bacteriostatic agents
  • Contains amphotericin B as a fungistatic agent
  • Inactivate unused contents before disposal
  • Safety comparable to existing HVT vector vaccines10
  • Proven to remain safe and stable; will not revert to virulence11


  1. Data on file. Boehringer Ingelheim Animal Health.
  2. Merial Select, Inc., 2016, Report number 16-083.
  3. Merial Select, Inc., 2017, Report number 16-194.
  4. Boehringer Ingelheim R&D, 2018, Report number 16-0325.
  5. Merial Select, Inc., 2017, Report number 16–191.
  6. Merial Select, Inc., 2018, Report number 16–190.
  7. Merial Select, Inc., 2017, Report number 16–0499.
  8. Merial Select, Inc., 2018, Report number 16-189.
  9. Merial Select, Inc., 2018, Report number 17-111.
  10. Merial Select, Inc., 2017, Report number 16-187.
  11. Boehringer Ingelheim R&D, 2017, Report number 17.0107.R.

VAXXITEK® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. © 2020 Animal Health USA Inc. All Rights Reserved. US-POU-0043-2019

Product Resources

Contact Information

  • Boehringer Ingelheim Animal Health USA Inc.

    Poultry Business Unit

    3239 Satellite Blvd.
    Duluth, GA 30096